Immune Checkpoint Specific Single Domain Antibody (SdAb) Development Solution
Application & Development Workflow Features Case Study
Single domain antibody (sdAb) has the potential as novel immune checkpoint therapeutic with a series of advantageous properties. Based on our deep understanding of various immune checkpoints, Creative Biolabs presently builds up a
one-stop solution for immune checkpoint specific sdAb development to meet our customers' specific requirements in both therapeutic and diagnostic applications. Leveraging advanced platforms and cutting-edge technologies, we are confident in providing
the most appropriate solutions and achieving optimal outcomes for our clients.
Immune checkpoints are regulatory pathways within the immune system that ensure self-tolerance and prevent autoimmune responses. Tumor cells frequently exploit these pathways to evade immune detection, particularly by inhibiting T cells that target tumor-specific
antigens. Consequently, the targeted modulation of these stimulatory or inhibitory immune checkpoints has garnered significant attention as a novel therapeutic approach for cancer treatment.
Applications of Immune Checkpoint Specific SdAb
Immunotherapy utilizing checkpoint inhibitors has shown remarkable advancements in cancer treatment. Notable inhibitory immune checkpoints include CTLA-4, PD-1, and PD-L1. Recently, single domain antibodies (sdAbs) targeting these checkpoints have been
effectively employed in treating various cancers due to their potent antitumor activity. The smaller size, high binding affinity and specificity, and favorable physicochemical properties of sdAbs make them promising candidates for the design and optimization
of immune checkpoint inhibitors as therapeutic agents.
Furthermore, single domain antibodies (sdAbs) targeting immune checkpoints represent a promising tool for molecular imaging, aiding in patient selection and treatment monitoring. These sdAbs exhibit exceptional imaging properties, including high tissue
(tumor) penetration, rapid blood clearance, and renal elimination, which result in high-contrast images within hours post-injection. Collectively, immune checkpoint-specific sdAbs offer a novel molecular framework for the advancement of enhanced immune
checkpoint-based therapies and affinity agents for molecular imaging and in vitro diagnostics.
Immune Checkpoint Specific SdAb Development at Creative Biolabs
Creative Biolabs possesses extensive expertise in the successful identification of single domain antibodies (sdAbs) targeting a range of immune checkpoints. With our well-establish sdAb platform, Creative Biolabs offers a one-stop solution to tailor immune
checkpoint specific sdAb for our customers worldwide. To ensure the optimal application of these sdAbs, we collaborate closely with our clients to tailor each project and develop proposals that precisely meet their specific needs. These diverse services
will significantly facilitate your scientific and clinical research about immune checkpoint specific sdAb.
Typical Pathway for Immune Checkpoint Specific sdAb Development
Phase I Discovery
Target Identification Multiple target identification processes can be provided upon your request.
Phase II Characterization
Typical Features of One-Stop for Immune Checkpoint Specific SdAb Development
-
Advanced technical platform in dealing with different immune checkpoints.
-
Comprehensive strategies to formulate the most suitable solutions.
-
Experienced professional team with a wealth of knowledge.
-
Fully customizable design to meet specific demands.
-
Fast turnaround time.
-
Reliable lab report with timely update.
-
Affordable price with the best quality.
Creative Biolabs boasts unparalleled expertise in the discovery and development of single domain antibodies (sdAbs). Based on the most advanced platforms and powerful technologies, Creative Biolabs will offer custom solutions for
the development of sdAb specifically binding to the immune checkpoint as a new diagnostic and therapeutic agent in cancer management. If you are interested in our service, please feel free to contact us for more details.
Reference
-
Wierstra, Peter, et al. "Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer." EJNMMI Radiopharmacy and Chemistry 4 (2019): 1-20. Distributed under Open Access license CC BY 4.0, without modification.
We are offering highly customized CRO services to assist your Single Domain Antibody (sdAb) related projects. Please Contact Us for more details.